Skip to main content

Lucira Health, Inc.

LHDXDelisted Apr 12, 2023
Industry
In Vitro & In Vivo Diagnostic Substances
SEC CIK
0001652724

Lucira Health, Inc. was delisted on Apr 12, 2023; its insiders filed their last Form 4 on Mar 13, 2023; 29 institutions reported holding it in 13F filings for Q4 2022, worth $1.04M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Lucira Health, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of LHDX: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders4436−8
Shares16.3M17.7M+1.48M (+9.1%)
Value$107.9M$131.9M+$23.9M (+22.2%)

New holders (10)

Institutions that held Lucira Health, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to LHDX in Q3 2021
InstitutionSharesValue% of portfolio
MPM Oncology Impact Management LP578,114$4.39M0.68%
Silverarc Capital Management, LLC220,758$1.68M0.97%
FMR LLC57,684$438.0K0.00%
Citadel Advisors LLC51,382$391.0K0.00%
Papp L Roy & Associates45,850$348.0K0.04%
Resolute Partners Group22,800$173.0K0.02%
Johnson Financial Group, Inc.10,000$76.0K0.01%
Cutler Group LP1,400$10.0K0.00%
Signaturefd, LLC215$2.00K0.00%
US Bancorp40$00.00%

Sold out (18)

Institutions that held Lucira Health, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.